← Back to Home

Ipsen

Euronext Paris: IPN ↗ $156.50 EUR ~$9B (Euronext Paris) MCAP
#Oncology#Rare Disease#Neuroscience#Aesthetic Medicine (Botulinum Toxin)#Endocrinology / Neuroendocrine Tumors

Ipsen is a global specialty biopharmaceutical company focused on oncology, rare disease, and neuroscience, with a portfolio of in-market products including Dysport (botulinum toxin), Somatuline (lanreotide), and Onivyde (irinotecan). The company is advancing a refreshed R&D pipeline in 2026 with multiple Phase 3 readouts planned, alongside a new wave of partnership-led discovery deals.

Company Info

Sector: Pharmaceutical / Specialty Therapeutics
Headquarters: Paris, France (with major operations in the U.S. and U.K.)
Founded: 1929
Website: www.ipsen.com/

Upcoming Milestones & Key Dates

H2 2026
Clinical Trial

Phase 3 RESOLVE readout of Onivyde in first-line metastatic pancreatic cancer

Q3 2026
Earnings

H1 2026 earnings and pipeline update

Clinical Development Pipeline

Onivyde (irinotecan) + chemotherapy regimens

Target: Topoisomerase I inhibitor liposomal formulation
First-line metastatic pancreatic ductal adenocarcinoma (RESOLVE Phase 3 readout pending)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Cabozantinib-based combinations

Target: Multi-kinase inhibitor (c-MET, VEGFR2, AXL)
Solid tumors (multiple oncology combinations)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Tovorafenib (Ojemda)

Target: Type II RAF kinase inhibitor
Relapsed/refractory pediatric low-grade glioma (BRAF fusion-positive)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

David Loew

Chief Executive Officer

To be confirmed

Head of Research and Development

To be confirmed

Chief Medical Officer

Careers & Job Openings

See all open roles

Multiple Departments
See careers page
Apply Now →